Maximilian Merz1, Jens Hillengass2, Hartmut Goldschmidt2,3. 1. Department of Hematology, Oncology and Rheumatology, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. maximilian.merz@med.uni-heidelberg.de. 2. Department of Hematology, Oncology and Rheumatology, University Hospital of Heidelberg, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany. 3. National Center for Tumor Diseases, Heidelberg, Germany.
Abstract
PURPOSE: The 5th Heidelberg Myeloma Workshop was held on April 24 and 25, 2015, in the lecture hall of the department of internal medicine of the University Hospital of Heidelberg, Germany. METHODS AND RESULTS: Main topics of the meeting were (1) new insights into biology of plasma cell diseases, (2) familial risk in multiple myeloma (MM), (3) diagnosis and prognostic factors in MM and early plasma cell diseases, (4) frontline therapy in transplant-eligible and (5) transplant-ineligible patients as well as (6) treatment of relapsed disease. CONCLUSION: Better understanding of disease biology led to tremendous changes in the treatment of multiple myeloma in recent years and were reported during the meeting.
PURPOSE: The 5th Heidelberg Myeloma Workshop was held on April 24 and 25, 2015, in the lecture hall of the department of internal medicine of the University Hospital of Heidelberg, Germany. METHODS AND RESULTS: Main topics of the meeting were (1) new insights into biology of plasma cell diseases, (2) familial risk in multiple myeloma (MM), (3) diagnosis and prognostic factors in MM and early plasma cell diseases, (4) frontline therapy in transplant-eligible and (5) transplant-ineligible patients as well as (6) treatment of relapsed disease. CONCLUSION: Better understanding of disease biology led to tremendous changes in the treatment of multiple myeloma in recent years and were reported during the meeting.
Authors: Jonathan P GroΔ; Johanna Nattenmüller; Stefan Hemmer; Diana Tichy; Julia Krzykalla; Hartmut Goldschmidt; Uta Bertsch; Stefan Delorme; Hans-Ulrich Kauczor; Jens Hillengass; Maximilian Merz Journal: Oncotarget Date: 2017-07-25